1. Name and Address of Reporting Person  
Kamal Mostafa  
15950 NORTH 76TH STREET  
SUITE 200  
SCOTTSDALE AZ  
85260

2. Issuer Name and Ticker or Trading Symbol  
MAGELLAN HEALTH INC [ MGLN ]

3. Date of Earliest Transaction (Month/Day/Year)  
12/09/2019

4. If Amendment, Date of Original Filed  
4. If Amendment, Date of Original Filed  
12/11/2019

5. Relationship of Reporting Person(s) to Issuer  
Director  
X  
Officer (give title below)  
CEO, Magellan Rx Management

6. Individual or Joint/Group Filing (Check Applicable Line)  
X Form filed by One Reporting Person  
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Common Stock, $0.01 par value</td>
<td>12/09/2019</td>
<td>X(1)</td>
<td>16,666</td>
<td>A</td>
<td>$60.55</td>
<td>19,459</td>
<td>D</td>
</tr>
<tr>
<td>Ordinary Common Stock, $0.01 par value</td>
<td>12/09/2019</td>
<td>X(1)</td>
<td>100</td>
<td>A</td>
<td>$64.87</td>
<td>19,559</td>
<td>D</td>
</tr>
<tr>
<td>Ordinary Common Stock, $0.01 par value</td>
<td>12/09/2019</td>
<td>S(1)</td>
<td>16,766</td>
<td>D</td>
<td>$78.7154(2)</td>
<td>2,793</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>$60.55</td>
<td>12/09/2019</td>
<td>X(1)</td>
<td>16,666</td>
<td>(3)</td>
<td>08/03/2025</td>
<td>Common Stock</td>
<td>16,666</td>
<td>$0.00(4)</td>
<td>0</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (right to buy)</td>
<td>$64.87</td>
<td>12/09/2019</td>
<td>X(1)</td>
<td>100</td>
<td>(3)</td>
<td>03/03/2026</td>
<td>Common Stock</td>
<td>100</td>
<td>$0.00(4)</td>
<td>7,206</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b-5-1 Plan.
2. The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $78.15 to $80.00, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
3. All of the stock options in this tranche have vested in full.
4. Not applicable.

Remarks:

/s/ Mostafa Kamal  
12/11/2019  
** Signature of Reporting Person  
Date